Still, chronic treatment with caffeine during the degenerative phase of MS animal model provides neuroprotection regardless of the A2AR genotype, implying that, in this disease, caffeine acts in a non-A2AR-dependent manner [169]. Here, ADORA2A is linked to myeloid sarcoma.